

Jong Young Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1356959/publications.pdf>

Version: 2024-02-01

86
papers

1,865
citations

279798

23
h-index

330143

37
g-index

88
all docs

88
docs citations

88
times ranked

3040
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. <i>Hepatology</i> , 2015, 61, 1809-1820.	7.3	117
2	Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. <i>Scientific Reports</i> , 2019, 9, 3260.	3.3	106
3	Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. <i>Gut</i> , 2020, 69, 1301-1308.	12.1	101
4	Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. <i>World Journal of Gastroenterology</i> , 2013, 19, 339.	3.3	94
5	Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	3.0	73
6	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	3.9	66
7	Synergistic effects of CD44 and TGF- β 1 through AKT/GSK-3 β -catenin signaling during epithelial-mesenchymal transition in liver cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 568-574.	2.1	65
8	EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. , 2020, 8, e000301.		62
9	Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. <i>Experimental and Molecular Medicine</i> , 2018, 50, e432-e432.	7.7	48
10	Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1954-1963.e3.	4.4	46
11	The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 1023-1031.	2.4	42
12	Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 242-252.	1.7	41
13	Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1503-1511.e2.	0.5	37
14	Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - a pilot study. <i>Liver International</i> , 2005, 25, 740-745.	3.9	29
15	¹⁸ F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 384-391.	6.4	29
16	Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. <i>Frontiers in Oncology</i> , 2020, 10, 1043.	2.8	29
17	Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0122041.	2.5	28
18	Serial Monitoring of Immune Markers Being Represented Regulatory T Cell/T Helper 17 Cell Ratio: Indicating Tolerance for Tapering Immunosuppression after Liver Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 352.	4.8	28

#	ARTICLE	IF	CITATIONS
19	Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 235.	3.3	28
20	IL-1 Receptor Blockade Alleviates Graft-versus-Host Disease through Downregulation of an Interleukin-1 γ -Dependent Glycolytic Pathway in Th17 Cells. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	3.0	27
21	IL-17 axis accelerates the inflammatory progression of obese mice via TBK1 and IKK β pathway. <i>Immunology Letters</i> , 2017, 184, 67-75.	2.5	26
22	A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. <i>Journal of Clinical Medicine</i> , 2020, 9, 4121.	2.4	26
23	Treatment Algorithm for Intermediate and Advanced Stage Hepatocellular Carcinoma: Korea. <i>Oncology</i> , 2011, 81, 141-147.	1.9	25
24	Ursodeoxycholic Acid Ameliorates Pain Severity and Cartilage Degeneration in Monosodium Iodoacetate-Induced Osteoarthritis in Rats. <i>Immune Network</i> , 2014, 14, 45.	3.6	24
25	A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 128-137.	8.9	24
26	Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 2395.	3.3	24
27	A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. <i>Hepatology</i> , 2019, 70, 621-629.	7.3	23
28	HMGB1/RAGE induces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients. <i>Journal of Translational Medicine</i> , 2015, 13, 310.	4.4	22
29	Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 207-218.	8.9	22
30	Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 3909-3916.	1.1	19
31	Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, 546-555.	5.8	19
32	A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2022, 77, 632-641.	3.7	19
33	Clinical Characteristics and Outcomes of Acute Hepatitis A in Korea: A Nationwide Multicenter Study. <i>Journal of Korean Medical Science</i> , 2014, 29, 248.	2.5	18
34	Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE. <i>Immunology Letters</i> , 2017, 188, 1-8.	2.5	18
35	Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression. <i>Scientific Reports</i> , 2019, 9, 9137.	3.3	18
36	Exosomal miR-125b Exerts Anti-Metastatic Properties and Predicts Early Metastasis of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 637247.	2.8	18

#	ARTICLE	IF	CITATIONS
37	Clinical significance of methicillin-resistant <i>Staphylococcus aureus</i> and vancomycin-resistant enterococci colonization in liver transplant recipients. Korean Journal of Internal Medicine, 2015, 30, 694-704.	1.7	18
38	Combination Treatment With Metformin and Tacrolimus Improves Systemic Immune Cellular Homeostasis by Modulating Treg and Th17 Imbalance. Frontiers in Immunology, 2020, 11, 581728.	4.8	17
39	Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling. Clinical and Molecular Hepatology, 2018, 24, 302-310.	8.9	17
40	Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. Hepatology International, 2016, 10, 470-477.	4.2	16
41	Impact of Enterococcal Bacteremia in Liver Transplant Recipients. Transplantation Proceedings, 2019, 51, 2766-2770.	0.6	16
42	Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma. Clinical Infectious Diseases, 2021, 73, e1372-e1375.	5.8	16
43	Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source. Annals of Transplantation, 2017, 22, 276-284.	0.9	16
44	Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant. Frontiers in Immunology, 2019, 10, 1319.	4.8	15
45	FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition. Journal of Translational Medicine, 2020, 18, 225.	4.4	15
46	Outcome of donor biliary complications following living donor liver transplantation. Korean Journal of Internal Medicine, 2018, 33, 705-715.	1.7	15
47	Intrahepatic inflammatory IgA ⁺ PD-L1 ^{high} monocytes in hepatocellular carcinoma development and immunotherapy. , 2022, 10, e003618.		15
48	Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 10271.	4.1	14
49	Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatology Research, 2016, 46, 657-668.	3.4	13
50	Adenovirus-mediated p53 tumor suppressor gene therapy against subcutaneous HuH7 hepatoma cell line nodule of nude mice. Journal of Korean Medical Science, 1999, 14, 271.	2.5	12
51	Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatology International, 2021, 15, 137-145.	4.2	12
52	Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clinical and Molecular Hepatology, 2016, 22, 458-465.	8.9	11
53	Clinical usefulness of kidney biopsy in liver transplant recipients with renal impairment. Kidney Research and Clinical Practice, 2013, 32, 153-157.	2.2	10
54	A Case of Pulmonary Arterial Hypertension Associated with Congenital Extrahepatic Portocaval Shunt. Journal of Korean Medical Science, 2014, 29, 604.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2992-3000.	2.3	10
56	Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 666-676.	2.2	10
57	Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 600233.	2.8	10
58	Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2022, 28, 397-406.	2.4	10
59	Expression of Notch 1 and 3 is related to inhibition of lymph node metastasis and progression in non-small cell lung carcinomas. <i>Basic and Applied Pathology</i> , 2008, 1, 93-97.	0.2	9
60	Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. <i>PLoS ONE</i> , 2017, 12, e0170362.	2.5	9
61	Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases. <i>Journal of Korean Medical Science</i> , 2016, 31, 1943.	2.5	8
62	Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 81-88.	2.3	8
63	Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. <i>Annals of Surgical Treatment and Research</i> , 2018, 95, 267.	1.0	8
64	Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. <i>Journal of Medical Virology</i> , 2019, 91, 1104-1111.	5.0	8
65	FK506 and <i>Lactobacillus acidophilus</i> ameliorate acute graft-versus-host disease by modulating the T helper 17/regulatory T-cell balance. <i>Journal of Translational Medicine</i> , 2022, 20, 104.	4.4	8
66	Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 615-626.	3.2	7
67	Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2039-2048.	2.3	7
68	Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 73, e892-e903.	5.8	7
69	Sustained off therapy response after pegylated interferon favours functional cure and no disease progression in chronic hepatitis B. <i>Liver International</i> , 2021, 41, 288-294.	3.9	6
70	Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant. <i>Frontiers in Pharmacology</i> , 2021, 12, 685176.	3.5	6
71	Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0260311.	2.5	6
72	Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1657-1666.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Use of M2BPGi in HCC patients with TACE. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2917-2924.	2.8	4
74	Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clinical and Molecular Hepatology, 2014, 20, 168.	8.9	4
75	A Case of Ulcerative Colitis Following Acute Hepatitis Induced by Epstein-Barr Virus Infection. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2016, 68, 104.	0.4	3
76	Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms. Clinical and Molecular Hepatology, 2020, 26, 78-82.	8.9	3
77	Relative skeletal muscle mass and non-alcoholic fatty liver disease: from association to causation. Hepatobiliary Surgery and Nutrition, 2019, 8, 509-511.	1.5	2
78	Patient-Derived Avatar Mouse Model to Predict the Liver Immune Homeostasis of Long-Term Stable Liver Transplant Patients. Frontiers in Immunology, 2022, 13, 817006.	4.8	2
79	Risk factors of biliary intervention by imaging after living donor liver transplantation. World Journal of Gastroenterology, 2016, 22, 2342-2348.	3.3	1
80	Two cases of common bile duct stone after liver transplantation. Journal of Korean Medical Science, 1999, 14, 97.	2.5	0
81	Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus. Cancer Control, 2021, 28, 107327482110397.	1.8	0
82	Acute-on-chronic liver failure due to infarction of multiple cirrhotic nodules. Liver International, 2021, 41, 1954-1955.	3.9	0
83	Alteration of Bile Acid Transporter Expression in Patients with Early Cholestasis Following Living Donor Liver Transplantation. Korean Journal of Pathology, 2009, 43, 48.	1.3	0
84	Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them. Clinical and Molecular Hepatology, 2018, 24, 374-383.	8.9	0
85	Unexpected Improvement of Liver Function by Intravenous Immunoglobulin in a Steroid-Experienced Severe Alcoholic Hepatitis. ACG Case Reports Journal, 2020, 7, e00337.	0.4	0
86	Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 30-39.	1.1	0